Biotek-snakken — April 2026
-
Initiator Pharma A/S rapporterer fremskridt i patientrekrutteringen til fase 2a-studie i vulvodyni https://www.nordnet.dk/markedet/nyheder/4a963de2-45da-4f01-9de5-b12683953745
-
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 million milestone payment, bringing total potential cash ...
Yahoo Finance (finance.yahoo.com)
-
Initiator Pharma A/S: Enrolment on track - fair value range 6,8–9,3 SEK (DNB Carnegie)
Recruitment in the important vulvodynia study appears to be on track, with half of the planned patients already dosed. We find the positive development encouraging. We believe a positive outcome could represent a key value inflection point, and estimate peak sales of approximately USD1.6bn, risk-adjusted at a 15% LOA. https://access.dnbcarnegie.com/publication/e46d158f-68fe-43f0-58cb-08dea508df61
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind